Click on headlines below to download research
Positive data in non-randomised MOJAVE cohort
Sequana Medical | 04/12/2023
Sequana Medical has announced interim results from all three patients comprising the non-randomised cohort of its MOJAVE US Phase I/IIa study evaluating…
MOJAVE early efficacy validates DSR 2.0
Sequana Medical | 13/11/2023
Sequana Medical recently announced positive interim data, from the non-randomised cohort of the Phase I/IIa MOJAVE study, in patients with chronic heart…
On track to meet key milestones
Sequana Medical | 25/09/2023
Sequana Medical has affirmed its guidance for its two lead programmes, the implantable alfapump device for recurrent and refractory ascites (RRA) and Direct…
MOJAVE enrols first patient
Sequana Medical | 12/07/2023
Sequana Medical announced that it has enrolled the first patient in the open-label cohort of its MOJAVE US Phase I/IIa study evaluating its second-generation…
Additional POSEIDON data confirm benefits
Sequana Medical | 28/06/2023
Sequana Medical has reported additional data on safety, quality of life (QoL) and survival from the POSEIDON North American open-label pivotal study assessing…
New funding to support clinical progression
Sequana Medical | 02/05/2023
Sequana Medical has raised €15.8m through a private placement of new shares and subscription rights. Roughly 4.445m new shares were issued at €3.55/share,…